We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 164.25 | 334 | 11:09:33 |
From Apr 2019 to Apr 2024
AbbVie Inc.'s third-quarter revenue from its immunology portfolio was $5.79 billion, a 14.8% increase year over year. That result included revenue from AbbVie's Humira medication of $5.14 billion, a figure that rose 4.1% year over year. "AbbVie Logs 3Q Sales Growth on Higher Immunology, Oncology Results," published at 8:07 a.m. ET, incorrectly said that immunology revenue increased 4.1%, to $5.14 billion.
(END) Dow Jones Newswires
October 30, 2020 09:50 ET (13:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
